Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lisocabtagene maraleucel - Juno Therapeutics

Next Previous
Drug Profile

Lisocabtagene maraleucel - Juno Therapeutics

Alternative Names: anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; Breyanzi; CD19-directed chimeric antigen receptor T cell therapy - Juno Therapeutics; EGFRt-4-1BB-modified-CAR-CD8+-and-CD4+-T-lymphocytes-Juno-Therapeutics; Gene modified autologous T cells; JCAR 017; Liso-cel

Latest Information Update: 17 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juno Therapeutics
  • Developer Bristol-Myers Squibb; Celgene Corporation; Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Preregistration Non-Hodgkin's lymphoma
  • Phase II B-cell lymphoma; Hodgkin's disease
  • Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 05 Feb 2026 Preregistration for Marginal zone B-cell lymphoma (Second-line therapy or greater) in Japan (IV) (Bristol-Myers Squibb pipeline, February 2026)
  • 08 Dec 2025 Efficacy and adverse events data from the TRANSCEND FL phase II trial in Marginal zone lymphoma released by Bristol-Myers Squibb
  • 08 Dec 2025 Updated efficacy data from a phase III TRANSFORM trial in Diffuse large B-cell lymphoma released by Bristol-Myers Squibb

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top